Select your country
Select a country to go to the website of the respective STADA sales company.
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (4)
STADA: Appointment of Dr. Matthias Wiedenfels extended
- Press Release
Bad Vilbel, January 11, 2016 –
On January 8, 2016, the Supervisory Board of STADA Arzneimittel AG extended the appointment of Dr. Matthias Wiedenfels as Chief Business Development & Central Services Officer by four years until December 31, 2020. Dr. Wiedenfels has been a Member of STADA’s Executive Board since 2013. His previous contract would have ended on December 31, 2016. Within the Executive Board, Dr. Wiedenfels is responsible for the areas of Business Development, Portfolio Management, Human Resources, Legal, IP/Patents, Compliance (including Export Control), Risk Management, as well as for Quality Assurance and Quality Control.
“I’m very pleased about this repeated sign of confidence and about the opportunity to continue the successful cooperation with my two colleagues in the Executive Board in the coming years. In addition to the challenges that lie ahead of us, we are also facing some great opportunities, which we will take advantage of to pursue STADA’s sustainable development goals. This includes the further acceleration of the internationalization strategy through value-enhancing acquisitions”, says Dr. Wiedenfels about the plans in connection with the extension of his contract.
The extension of the appointment of Dr. Wiedenfels and last year’s extension of the appointment of the Chairman of the Executive Board and the Chief Financial Officer ensure the continued stability in the Executive Board of STADA Arzneimittel AG. The STADA Executive Board continues to consist of Hartmut Retzlaff, Chairman, Helmut Kraft, Chief Financial Officer, and Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer.
Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: email@example.com
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org